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Abstract: Clinical outcomes of patients with atrial fibrillation (AF) can be improved by an integrated
care approach. We analyzed whether adherence with the AF Better Care (ABC) pathway for integrated
care management would reduce the risk of dementia in a nationwide AF cohort. Using the National
Health Insurance Service database of Korea, 228,026 non-valvular AF patients were retrospectively
evaluated between 2005 and 2015. Patients meeting all criteria of the ABC pathway were classified
as the “ABC” group and those not classified as the “non-ABC” group. During a median (25th, 75th
percentiles) follow-up of 6.0 (3.3, 9.5) years, the ABC group had lower rates and risk of overall
dementia (0.17 vs. 1.11 per 100 person-years, p < 0.001; hazard ratio (HR) 0.80; 95% CI 0.73–0.87) and
both Alzheimer’s (HR 0.79, 95% CI 0.71–0.88) and vascular dementia (HR 0.76, 95% CI 0.59–0.98)
than the non-ABC group. The stratified analysis showed that the ABC pathway reduced the risk of
dementia regardless of sex, comorbidities, and in patients with high stroke risk. Adherence with the
ABC pathway is associated with a reduced risk of dementia in AF patients. Due to the high medical
burden of AF, it is necessary to implement integrated AF management to reduce the risk of dementia.
Keywords: atrial fibrillation; dementia; integrated; Alzheimer
1. Introduction
Atrial fibrillation (AF) is the most common cardiac arrhythmia and is therefore a substantial
economic and public health burden [1,2]. The age distribution of AF is predicted to shift with
an expected increase in prevalence among the elderly [2]. AF increases the risk of mortality and
morbidity with a concurrent increase in associated conditions including stroke, congestive heart failure,
and hospitalization. AF also increases the occurrence of comorbid chronic diseases [3]. Little is known
about the pathophysiological mechanisms of dementia, but there is increasing evidence that AF is
related to cognitive dysfunction and dementia [4–7].
Recent trials involving AF revealed a high (4.6% per year) rate of all-cause death in patients
with AF, with only 10% of deaths related to stroke and approximately 50%–60% deaths related to
cardiovascular causes [8,9]. Therefore, recent AF guidelines advocated a more integrated approach
beyond anticoagulation therapy for patients with AF to reduce death and adverse outcomes in
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AF [10–12]. The ABC (atrial fibrillation Better Care) pathway has been proposed as such a simple and
holistic integrated approach [13]. This pathway facilitates the care pathway as follows: “A”—avoid
stroke with optimal anticoagulation; “B”—better symptom management; and “C”—cardiovascular
and comorbidity management [13]. The application of the simple ABC pathway was associated with a
lower risk of all-cause death and the composite outcome included all-cause death, ischemic stroke,
myocardial infarction, or major bleeding in patients with AF [14–16]. However, population-based
benefits for total dementia, Alzheimer’s, or vascular dementia due to adherence to the ABC pathway
in AF pathway patients have not been previously assessed in AF patients. Given the close association
between AF and dementia, this study aimed to evaluate whether compliance with the ABC pathway
would improve the risk of dementia in patients with AF.
2. Experimental Section
All data and materials have been made publicly available at the National Health Insurance Service
(NHIS) of Korea. The data can be accessed on the National Health Insurance Data Sharing Service
homepage of the NHIS (http://nhiss.nhis.or.kr). This study was a retrospective cohort analysis using
the national health claims database (NHIS-2016-4-009) established by the NHIS of Korea [1,2,17].
The NHIS is the single insurer managed by the Korean government, and the majority (97.1%) of the
Korean population are mandatory subscribers, with the remaining 3% of the population being medical
aid subjects. The NHIS claims database includes diagnoses, biochemical test results, prescription
records, procedures, and demographic information. This study was approved by the Institutional
Review Board of Yonsei University Health System (4-2016-0179).
2.1. Study Cohort
In the Korean NHIS database, a total of 955,111 patients with prevalent AF over 18 years of age
were identified from January 1, 2005 to December 31, 2015. Patients with valvular AF, such as those
with rheumatic mitral stenosis, or surgery of heart valves (n = 59,189), those without baseline health
check-up data up to 1 year before enrolment (n = 571,585), those who had ischemic stroke (n = 61,350),
and those with history of dementia (n = 5915) were excluded. Patients with ischemic stroke during
the follow-up period were additionally excluded (n = 29,046). Finally, a total of 228,026 patients
with non-valvular AF were enrolled in the study to evaluate the effect of the ABC pathway on the
development of dementia (Figure 1).
AF was diagnosed using the International Classification of Disease 10th revision code I48. To ensure
diagnostic accuracy, AF was defined as being present only if it was a discharge diagnosis or confirmed
more than once in the outpatient department. The diagnosis of AF was previously verified in the NHIS
database with a positive predictive value of 94.1% [2,18–20].
2.2. Definition of the ABC Pathway-Compliant Group
The ABC pathway was defined according to the criteria outlined in Supplementary Figure S1.
“A” was defined as stroke prevention in accordance with the guidelines [12]. The patients with optimal
anticoagulation included those with a high adherence of oral anticoagulants with a prescription
covering ≥80% of days; “B” was defined in relation to visits requiring medical contact with an
outpatient clinic (less than 5 visits per year during the tracking period); “C” was defined as optimal
management of comorbidities and obesity. Optimal management of hypertension was defined as
baseline systolic blood pressure values less than 140 mmHg and diastolic blood pressure values less
than 90 mmHg. For other comorbidities including heart failure, myocardial infarction, peripheral
artery disease, stroke/transient ischemic attack (TIA), and diabetes mellitus, the appropriate use of
cardiovascular medications according to current guidelines was considered optimal management.
For obesity, a body mass index less than 30 kg/m2 was considered optimal management. Patients
meeting all criteria were classified as the “ABC” group and those not classified as the “non-ABC” group.
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Figure 1. Flowchart of study population enrolment. ABC, atrial fibrillation better care; AF, atrial 
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Figure 1. Flowchart of study population enr l t. ABC, atrial fibrillation bette care; AF, atrial
fibrillation; OAC, oral anticoagulant; NHIS, National ealth Insurance Service.
2.3. Covariates, Primary and Secondary Outcome
Information regarding the comorbidity conditions was obtained from inpatient and outpatient
hospital diagnoses. Baseline comorbidities were defined using medical claims and prescription
medications before the index date. Similar to previous studies using NHIS data, the patients were
considered to have comorbidities when the condition was a discharge diagnosis or was confirmed at
least twice in an outpatient setting (Supplementary Table S1) [1,2,7,17,18,21].
The primary outcome was the initial occurrence of overall dementia. Secondary outcomes
included the development of dementia subtypes, including Alzheimer’s disease and v scul r dementia.
Medical expenditu e for demen ia patie ts is covered by he Korean governm nt. For the diagnosis
of dementia, we sed the following ICD-10 c des of dementia (F00 or G30 for Alzheimer’s disease,
F01 for vascular dementia, F02 for dementia with other diseases classified elsewhere, and F03 or G31
for unspecified dementia) and dementia drugs (rivastigmine, galantamine, memantine, or donepezil).
To access the accuracy of the dementia definitions, validation studies were conducted in two teaching
hospitals with a total of 972 patients using patient medical records and the results of cognitive function
tests. The positive predictive value was 94.7% [7].
Patients were followed up from the index date until the date of occurrence of the study outcomes,
or until the end of follow-up, whichever came first. Each endpoint was analyzed independently from
the others.
2.4. Statistical Analysis
Categorical data are reported as proportions, while continuous data are reported as medians with
25th and 75th percentiles. Baseline characteristics between outcomes between the ABC (i.e., integrated
care) and non-ABC groups were compared using Student’s t-test and Pearson’s chi-square test.
Event rates were defined as events per 100 person-years at risk but expressed as annualized percentage
rates for comprehensiveness. The relationships between the total number of ABC criteria fulfilled
and the clinical outcomes were also investigated. Cox proportional hazards regressions were used to
compare adverse outcomes between the ABC and non-ABC groups. Clinical variables including age,
sex, economic status, heart failure, hypertension, diabetes, myocardial infarction, peripheral arterial
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disease CHA2DS2-VASc score, and modified HAS-BLED score were adjusted. p-values < 0.05 were
considered significant. Statistical analyses were conducted using SAS version 9.3 (SAS Institute, Cary,
NC, USA) and R version 3.3.2 (The R Foundation, www.R-project.org).
3. Results
3.1. Baseline Characteristics
Comparisons between the ABC and non-ABC groups are presented in Table 1. Compared with
the non-ABC group, patients in the ABC group had a lower median age (49 vs. 64 years, p < 0.001),
and a lower prevalence of comorbidities. In addition, patients in the ABC group had lower mean
CHA2DS2-VASc and modified HAS-BLED scores than that of patients in the non-ABC group.
Table 1. Comparison of clinical characteristics between atrial fibrillation patients compliant with and




(n = 45,994) p-Value
Age, years 64 (55–71) 49 (41–57) <0.001
Female 70,218 (38.6) 18,016 (39.2) 0.019
Economic status 12 (5,17) 13 (6,17) <0.001
CHA2DS2-VASc score 2 (1, 3) 0 (0, 1) <0.001
mHAS-BLED score * 2 (1, 3) 0 (0, 1) <0.001
Charlson comorbidity index 3 (1, 4) 1 (0, 2) <0.001
Heart failure 41,557 (22.8) 627 (1.4) <0.001
Hypertension 117,688 (64.7) 2425 (5.3) <0.001
Diabetes 35,819 (19.7) 807 (1.8) <0.001
Myocardial infarction 12,838 (7.1) 157 (0.3) <0.001
Vascular disease 27,489 (15.1) 383 (0.8) <0.001
Chronic kidney disease 6089 (3.3) 358 (0.8) <0.001
Liver disease 70,974 (39.0) 13,365 (29.1) <0.001
Malignancy 36,768 (20.2) 6876 (14.9) <0.001
Hyperthyroidism 16,121 (8.9) 3498 (7.6) <0.001
Hypothyroidism 13,870 (7.6) 2629 (5.7) <0.001
COPD 23,033 (12.7) 1735 (3.8) <0.001
History of bleeding 12,525 (6.9) 1667 (3.6) <0.001
Medication
Oral anticoagulants (Baseline) 5822 (3.2) 1166 (2.5) <0.001
Oral anticoagulants (Follow-up) 46,569 (25.6) 7705 (16.8) <0.001
Antiplatelet agents 68,141 (37.4) 2339 (5.1) <0.001
Beta blocker 59,148 (32.5) 2794 (6.1) <0.001
Statin 44,226 (24.3) 2791 (6.1) <0.001
Calcium channel blocker 69,697 (38.3) 1664 (3.6) <0.001
ACE-inhibitor/ARB 66,533 (36.6) 1605 (3.5) <0.001
Antiarrhythmic drugs † 7087 (3.9) 544 (1.2) <0.001
ABC = atrial fibrillation Better Care, ACE = angiotensin converting enzyme, AF = atrial fibrillation, ARB = angiotensin
II receptor blocker, COPD = chronic obstructive pulmonary disease. * Modified HASBLED = hypertension,
1 point; >65 years old, 1 point; stroke history, 1 point; bleeding history or predisposition, 1 point; liable
international normalized ratio, not assessed; ethanol or drug abuse, 1 point; drug predisposing to bleeding,
1 point. † Antiarrhythmic drugs included class Ic arrhythmic drugs (e.g., flecainide, propafenone, pilsicainide),
and class III drugs (e.g., sotalol, dronedarone, amiodarone). Values are presented as numbers (%) or median (Q1,
Q3, quartiles (25th and 75th percentiles)).
The multivariable analysis showed that female, high economic status, chronic kidney disease,
chronic obstructive pulmonary disease (COPD), and history of malignancy were related to compliance
with the ABC pathway (Table 2). However, older age, heart failure, hypertension, and other
comorbidities were related to non-compliance with the ABC pathway.
J. Clin. Med. 2020, 9, 1696 5 of 11
Table 2. Factors associated with the ABC pathway.
Multivariable Adjustment
OR (95% CI) p-Value
Age (per 10-year increase) 0.91 (0.90–0.91) <0.001
Female 1.05 (1.05–1.05) <0.001
High economic status 1.02 (1.01–1.02) <0.001
Heart failure 0.97 (0.96–0.97) <0.001
Hypertension 0.76 (0.76–0.76) <0.001
Diabetes 0.93 (0.92–0.93) <0.001
Myocardial infarction 0.96 (0.95–0.96) <0.001
Peripheral arterial disease 0.97 (0.96–0.97) <0.001
Chronic kidney disease 1.02 (1.01–1.03) <0.001
COPD 1.02 (1.01–1.02) <0.001
Liver disease 0.98 (0.98–0.98) <0.001
Malignancy 1.02 (1.01–1.02) <0.001
Hyperthyroidism 0.98 (0.98–0.99) <0.001
Hypothyroidism 0.99 (0.99–1.00) 0.011
Intracranial hemorrhage 0.97 (0.95–0.98) <0.001
COPD = chronic obstructive pulmonary disease.
3.2. Dementia
During a median (25th, 75th percentiles) follow-up of 6.0 (3.3, 9.5) years, patients compliant with
the ABC pathway had significantly lower cumulative incidences of dementia than those not compliant
with the ABC pathway (Figure 2, Log rank p-value < 0.001).J. Clin. Med. 2020, 9, x FOR PEER REVIEW 6 of 11 
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Patients following the ABC pathway had significantly lower cumulative incidences of both 
Alzheimer’s and vascular dementia than those not following the ABC pathway (Figure 3, Log rank 
p-value < 0.001).  
Figure 2. Cumulative incidences of dementia according to the use of integrated care (ABC).
Compared with the non-ABC group, the ABC group had lower rates of dementia (0.17 vs. 1.11
per 100 person-years, p < 0.001). The adjustment of the clinical variables showed that ABC-compliant
patients were associated with a 20% lower risk of dementia than non-ABC-compliant patients
(hazard ratio (HR) 0.80, 95% confidence interval (CI) 0.73–0.87) (Table 3). Factors associated with the
increased risk of dementia were older age (per 10 year increase, HR 3.28, 95% CI 3.15–3.43, p < 0.001),
diabetes mellitus (HR 1.23, 95% CI 1.15–1.32, p < 0.001), and a higher CHA2DS2-VASc (per 1 score
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increase, HR 1.10, 95% CI 1.04-1.15, p < 0.001) or HAS-BLED score (per 1 score increase, HR 1.07, 95%
CI 1.05–1.10, p < 0.001).
Table 3. Dementia, Alzheimer’s, and vascular dementia hazard ratios for the non-ABC vs. ABC groups.
Cases, n (%) Event Rate(/100 Person-Years)





Non-ABC 12,165 1.11 (1.09–1.13) 1 (Reference) 1 (Reference)
ABC 538 0.17 (0.16–0.19) 0.74 (0.68–0.81) 0.80 (0.73–0.87)
Alzheimer’s dementia
Non-ABC 9731 0.88 (0.86–0.90) 1 (Reference) 1 (Reference)
ABC 410 0.13 (0.12–0.14) 0.74 (0.67–0.82) 0.79 (0.71–0.88)
Vascular dementia
Non-ABC 1274 0.11 (0.11–0.12) 1 (Reference) 1 (Reference)
ABC 72 0.02 (0.18–0.29) 0.68 (0.53–0.88) 0.76 (0.59–0.98)
CI = confidence interval, HR = hazard ratio. * Clinical variables including age, sex, economic status, heart failure,
hypertension, diabetes, myocardial infarction, peripheral arterial disease CHA2DS2-VASc score, and modified
HAS-BLED score were adjusted.
3.3. Alzheimer’s and Vascular Dementia
Patients following the ABC pathway had significantly lower cumulative incidences of both
Alzheimer’s and vascular dementia than those not following the ABC pathway (Figure 3, Log rank
p-value < 0.001).J. Clin. Med. 2 2 , 9, x FOR PEER REVIEW 7 of 11 
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Figure 3. Cumulative incidences according to the use of integrated care (ABC). (A) Alzheimer’s
de entia. (B) Vascular dementia.
Co pared with the non-ABC group, the ABC group had lower rates of Alzheimer’s dementia
(0.13 vs. 0.88 per 100 person-years, p < 0.001) and vascular dementia (0.02 vs. 0.11 per 100 person-years,
p < 0.001). ABC-compliant patients were associated with a 21% lower risk of Alzheimer’s dementia
(adjusted HR 0.79, 95% CI 0.71–0.88) and 24% lower risk of vascular dementia (adjusted HR 0.76, 95%
CI 0.59–0.98) than non-ABC-compliant patients (Table 3).
3.4. Subgroup Analysis
The stratified analysis showed that the ABC pathway reduced the risk of dementia regardless
of sex, heart failure, hypertension, diabetes, and in patients with high stroke risk. AF ablation was
perfor ed in 4293 (2.4%) and 1318 (3.0%) in the non-ABC and ABC groups, respectively. The ABC
path ay as related to a lo er risk of de entia only in those ithout catheter ablation of F (Figure 4).
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The risk of dementia for the non-ABC vs. ABC groups in different age subgroups is presented
in Table 4. With the full adjustment, the ABC group had a significantly lower risk of dementia than
the non-ABC group in elderly subjects (≥ 70 years; HR 0.82, 95%CI 0.69–0.98). With the age and sex
adjustment, a lower risk was evident for age ≥60 (HR 0.86; 95%CI 0.75–0.99).
Table 4. Risk of dementia for the non-ABC vs. ABC groups in different age subgroups.
Cases, n (%) Event Rate(/100 Person-Years)




≥70 years (n = 57,480)
Non-ABC 8186 3.05 (2.98–3.11) 1 (Reference) 1 (Reference)
ABC 129 2.22 (1.86–2.64) 0.83 (0.70–0.99) 0.82 (0.69–0.98)
≥60 and <70 years (n = 67,073)
Non-ABC 3415 0.89 (0.86–0.92) 1 (Reference) 1 (Reference)
ABC 221 0.52 (0.45–0.59) 0.86 (0.75–0.99) 0.93 (0.81–1.08)
≥50 and <60 years (n = 56,161)
Non-ABC 503 0.18 (0.17–0.20) 1 (Reference) 1 (Reference)
ABC 147 0.15 (0.13–0.18) 0.92 (0.77–1.11) 1.05 (0.84–1.30)
<50 years (n = 47,312)
Non-ABC 61 0.03 (0.03–0.04) 1 (Reference) 1 (Reference)
ABC 41 0.02 (0.02–0.03) 0.86 (0.58–1.30) 0.94 (0.58–1.54)
CI = confidence interval, HR = hazard ratio. * Clinical variables including age, sex, economic status, heart failure,
hypertension, diabetes, myocardial infarction, peripheral arterial disease CHA2DS2-VASc score, and modified
HAS-BLED score were adjusted.
4. Discussion
In this largest nationwide population-based study, our principal findings were as follows: (i) the
event rates and risks of overall dementia were all significantly lower in the ABC group than in the
non-ABC group; (ii) compared with patients in the non-ABC group, those in the ABC group had a lower
risk of Alzheimer’s or vascular dementia; and (iii) the ABC group was associated with the reduced risk
of dementia regardless of sex, comorbidities, and in patients with high stroke risk. Given the high
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healthcare burden associated with AF, a streamlined holistic approach to the management of AF would
improve dementia in such patients.
4.1. AF and Dementia
There are approximately 40 million people living with dementia worldwide, and this number is
expected to increase with a rising aged population [22]. Little is known about the pathophysiological
mechanisms of dementia, but evidence is accumulating that AF may contribute to the development of
cognitive dysfunction and dementia [4,5]. According to the Rotterdam Study, cognitive dysfunction
was about two times more common in subjects with AF than in those without AF [4]. Since then,
several longitudinal studies have shown that AF is independently associated with an increased risk of
cognitive decline or dementia [5,7]. Kim et al. [7]. also found that the risk of dementia was increased
by 65% in patients with AF than those without AF, even after censoring for incident stroke. In addition,
the risk of both Alzheimer’s and vascular dementia was increased by incident AF.
4.2. Dementia and Integrated AF Management
The use of an integrated care approach to AF management has been associated with reduced
cardiovascular hospitalisation and all-cause mortality [23]. The ABC pathway was proposed to
streamline interventions and decision-making, and to optimize the patient management pathway,
providing simple guidance for the key components of integrated care [13]. Recent AF management
guidelines have incorporated the ABC pathway [12,24]. Yoon et al. [16] showed that the following the
ABC pathway was associated with improved clinical outcomes in patients with AF. Compliance to the
ABC pathway was also associated with a lower risk of stroke, heart failure, and acute MI, as well as
major bleeding, in patients with AF [16].
In this study, the ABC group showed a reduced risk of overall and both Alzheimer’s or vascular
dementia in patients with AF. In the age subgroup analysis, with the full adjustment, the ABC group
had a significantly lower risk of dementia than the non-ABC group in elderly subjects (≥70 years).
With the age and sex adjustment, a lower risk was evident for age ≥60, with point estimates for age
<60 suggestive of a modest benefit with ABC, but limited by small numbers and low event rates.
The reduction in dementia in the ABC group might be related to the adherence of oral
anticoagulation and the control of risk factors. We and other groups demonstrated that the use
of oral anticoagulants was linked with a decreased incidence of dementia, especially in the senior
population [7,25]. Ischemic stroke is closely related with the risk of dementia [7]. The adherent use of
NOAC showed a lower risk of ischemic stroke, which increases the risk of dementia, without increasing
the bleeding risk [26]. The decreased risk of ischemic stroke was observed in AF patients with a strict
control of blood pressure [18,21] or the glucose level [27]. A recent study showed that the strict control
of blood pressure was also related to the reduction in dementia [28].
The strong impact of the ABC pathway on dementia substantiates and strengthens the concept
that a holistic approach for integrated management is associated with a significant clinical benefit for
patients with AF.
4.3. Study Limitations
The present study has some limitations. Although administrative databases are increasingly used
for clinical studies, such researches can lead to inaccurate results due to coding errors. To minimize this
problem, we applied the definition that we had validated in previous studies using the Korean NHIS
database [1,2,7,17,18,21]. Second, we used a high adherence of oral anticoagulants with a prescription
covering ≥80% of days as a surrogate of optimal anticoagulation. However, we could not evaluate the
TTR data in the warfarin patients, or label adherence prescribing of non-vitamin K oral anticoagulants.
Third, this study defined the low frequency of medical contact as a better symptom of management.
However, a symptom is just one of the factors to decide the frequency of medical contact. Despite
these limitations, to the best of our knowledge, this study presents the largest nationwide population
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dataset available in the literature to investigate the relationship between integrated management and
dementia in patients with AF.
5. Conclusions
Compliance with the simple ABC pathway is associated with reduced dementia in patients
with AF. Due to the high healthcare burden associated with AF, such a streamlined holistic approach to
the management of AF should be implemented in order to reduce dementia in AF patients.
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